Tim Coughlin Joins Retrophin (RTRX)'s Board Of Directors

SAN DIEGO--(BUSINESS WIRE)--Retrophin, Inc. (NASDAQ:RTRX) today announced the addition of Tim Coughlin, C.P.A. to the Company's Board of Directors as a fifth independent director, effective March 31, 2015.

"We are pleased to welcome Tim to the Board of Directors," said Stephen Aselage, Chief Executive Officer of Retrophin. "Tim's financial oversight and expertise within the industry will provide invaluable guidance to Retrophin as we continue moving into our next phase of growth and generate significant value for our shareholders."

Suggested Articles

EQRx is adding a pair of PD-1/PD-L1 meds to its pipeline through a deal with CStone worth $150 million upfront but could net the latter $1.15 billion.

All eyes are on Pfizer’s COVID-19 vaccine work, but the Big Pharma has today quietly culled two midstage trials and one phase 1 test.

All subjects had lower extremity weakness after receiving antisense oligonucleotide GTX-102, leading Ultragenyx to pause the study.